Format

Send to

Choose Destination
Future Oncol. 2019 Apr 12. doi: 10.2217/fon-2019-0059. [Epub ahead of print]

IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.

Author information

1
IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, & Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
2
Institut Gustave Roussy, Université Paris Sud, 114, rue Edouard Vaillant, 94800 Villejuif, France.
3
Aix-Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), & Institut Paoli-Calmettes, Department of Medical Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), 232 Bvd Sainte-Marguerite, 13009 Marseille, France.
4
Breast Unit Essen, Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany.
5
Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Universidad Complutense, Madrid, Spain.
6
Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, Old Anatomy Building, Charterhouse Square, London EC1M 6BQ, UK.
7
University Breast Unit, National Center for Tumor Diseases, 69120 Heidelberg, Germany.
8
Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 4000 Reservoir Road NW, 120 Building D, Washington, DC 20057, USA.
9
F Hoffmann-La Roche, Hochstrasse, CH 4070 Basel, Switzerland.
10
Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA.
11
F Hoffmann-La Roche, Building 1, Grenzacherstrasse, CH 4070 Basel, Switzerland.
12
Department of Medical Oncology, National Cancer Center, 11 Hospital Drive, Singapore, 169690, Singapore.

Abstract

The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for programmed death-ligand 1 (PD-L1)-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining atezolizumab with first-line nab-paclitaxel for metastatic TNBC significantly improved progression-free survival and showed a clinically meaningful effect on overall survival in patients with PD-L1-positive tumors. The placebo-controlled randomized Phase III IMpassion132 (NCT03371017) trial is evaluating atezolizumab with first-line chemotherapy (capecitabine [mandatory in platinum-pretreated patients] or gemcitabine/carboplatin) for inoperable locally advanced/metastatic TNBC recurring ≤12 months after completing standard (neo)adjuvant anthracycline and taxane chemotherapy. Stratification factors are: visceral metastases, tumor immune cell PD-L1 status and selected chemotherapy. Patients are randomized to atezolizumab 1200 mg or placebo every 3 weeks with the chosen chemotherapy, continued until progression, unacceptable toxicity or withdrawal. The primary end point is overall survival.

KEYWORDS:

PD-L1; atezolizumab; capecitabine; carboplatin; gemcitabine; immunotherapy; overall survival; triple-negative breast cancer

PMID:
30977385
DOI:
10.2217/fon-2019-0059

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center